Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA to share full inspection reports with EU; Difficult week for Teva, J&J, Mylan
This week, Phispers brings you the latest from the world of biosimilars, with Samsung Bioepis tying
